Korsana Biosciences, Inc. (KRSA)
Korsana Biosciences, Inc. (KRSA) from its SEC filings: 2025 revenue $2.1 million (+4% vs the year before), net margin -170%, free cash flow -$3.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $2.1 million |
| Revenue growth | +4% |
| Net income | -$3.5 million |
| Net margin | -170.1% |
| Free cash flow | -$3.3 million |
| Diluted EPS | $-1.11 |
| Latest quarter (Q1 2026 (calendar)) revenue vs a year earlier | -100% |
| Cash | $1.4 million |
| Share count, 1 year | +40% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.